Sandoz Inc. has launched its generic Icatibant injection pre-filled syringe to treat acute attacks of HAE in adults 18 years and older. It is available immediately for US patients.
Sandoz has signed a US commercialization deal with Slayback Pharma, a company focused on producing complex generic and specialty pharmaceutical products, for this medicine, which is a generic equivalent to Takeda’s Firazyr (icatibant injection).
“We are eager to see the positive effects of making generic Icatibant available immediately to people living with this painful and disabling rare disease,” says Keren Haruvi, President, Sandoz. “This collaboration aligns with our goal to build our injectables portfolio and provide US patients access to affordable generic medicines that work the same as brand-name products.”
“With our strong developmental capabilities and Sandoz’s industry-leading commercialization of its extensive portfolio of generic medicines, we couldn’t be more excited to collaborate with Sandoz and help people living with HAE,” says Ted Smolenski, Vice President of Business Development at Slayback Pharma.